Glucagon-like peptide-1 analog: Difference between revisions
Jump to navigation
Jump to search
(New page: '''Glucagon-like peptide-1 analog'''s are a new class of drug for treatment of type 2 diabetes.<ref>http://www.medscape.com/viewarticle/578304 "Glucagon-like Peptide-1 Analogs ...) |
m (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}})) |
||
| (6 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''[[Glucagon-like peptide-1]] analog'''s are a new class of [[drug]] for treatment of [[type 2 diabetes]]. <ref>http://www.medscape.com/viewarticle/578304 "Glucagon-like Peptide-1 Analogs Other Than Exenatide" </ref> One of their advantages is that they have a lower risk of causing [[hypoglycemia]]. | |||
===Licenced:=== | |||
* [[exenatide]] (2005) | |||
===Under investigation: === | |||
* albiglutide | |||
* taspoglutide | |||
==References== | ==References== | ||
{{reflist}} | {{reflist|2}} | ||
{{Oral hypoglycemics and insulin analogs}} | {{Oral hypoglycemics and insulin analogs}} | ||
[[Category:Hormones]] | |||
[[Category:Drugs]] | |||
Latest revision as of 17:52, 4 September 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Glucagon-like peptide-1 analogs are a new class of drug for treatment of type 2 diabetes. [1] One of their advantages is that they have a lower risk of causing hypoglycemia.
Licenced:
- exenatide (2005)
Under investigation:
- albiglutide
- taspoglutide
References
- ↑ http://www.medscape.com/viewarticle/578304 "Glucagon-like Peptide-1 Analogs Other Than Exenatide"